Fig. 1From: Results of sub-analysis of a phase 2 study on trabectedin treatment for extraskeletal myxoid chondrosarcoma and mesenchymal chondrosarcomaKaplan-Meier plot of progression-free survival. Progression-free survival of five patients with EMCS and MCS randomized to the trabectedin group (−) and three patients with MCS randomized to the BSC group (−−−)Back to article page